Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions

Blood

Volumn 100, Issue 8, 2002, Pages 2996-3001

  Schop, Roelandt F J ^a,b   Michael Kuehl, W ^a,b   Van Wier, Scott A ^a,b   Ahmann, Gregory J ^a,b   Price Troska, Tammy ^a,b   Bailey, Richard J ^a,b   Jalal, Syed M ^a,b   Qi, Ying ^a,b   Kyle, Robert A ^a,b   Greipp, Philip R ^a,b   Fonseca, Rafael ^a,b  

^a MAYO CLINIC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN M;

ARTICLE; CHROMOSOME 14Q; CHROMOSOME 6Q; CONTROLLED STUDY; CYTOGENETICS; DIPLOIDY; DISEASE ASSOCIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE FREQUENCY; GENE LOCUS; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC STABILITY; GENOME; HUMAN; HUMAN CELL; INTERPHASE; LYMPHOMA; LYMPHOPLASMACYTIC LYMPHOMA; MAJOR CLINICAL STUDY; MALE; METAPHASE; PARAPROTEINEMIA; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; SOUTHERN BLOTTING; TUMOR CELL; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0037108295     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.8.2996     Document Type: Article

References (52)

1. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenström's macroglobulinemia: clinical features, complications, and management [review]. J Clin Oncol. 2000;18:214-226.
2. Gertz MA, Fonseca R, Rajkumar SV. Waldenström's macroglobulinemia [review]. Oncologist. 2000;5:63-67.
3. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [review]. Blood. 1994;84: 1361-1392.
4. Offit K, Parsa NZ, Filippa D, Jhanwar SC, Chaganti RS. t(9;14)(p13;q32) denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation. Blood. 1992;80:2594-2599.
5. Stapleton P, Weith A, Urbanek P, Kozmik Z, Busslinger M. Chromosomal localization of seven PAX genes and cloning of a novel family member, PAX-9. Nat Genet. 1993;3:292-298.
6. Ohno H, Furukawa T, Fukuhara S, et al. Molecular analysis of a chromosomal translocation, t(9; 14)(P13;q32), in a diffuse large-cell lymphoma cell line expressing the Ki-1 antigen. Proc Natl Acad Sci U S A. 1990;87:628-632.
7. Iida S, Rao PH, Nallasivam P, et al. The t(9; 14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood. 1996;88:4110-4117.
8. Iida S, Rao PH, Ueda R, Chaganti RS, Dalla-Favera R. Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32) [review]. Leuk Lymphoma. 1999;34:25-33.
9. Ohno H, Ueda C, Akasaka T. The t(9;14)(p13; q32) translocation in B-cell non-Hodgkin's lymphoma [review]. Leuk Lymphoma. 2000;36:435-445.
10. Barr FG. Chromosomal translocations involving paired box transcription factors in human cancer [review]. Int J Biochem Cell Biol. 1997;29:1449-1461.
11. Wakatsuki Y, Neurath MF, Max EE, Strober W. The B cell-specific transcription factor BSAP regulates B cell proliferation. J Exp Med. 1994; 179:1099-1108.
12. Urbanek P, Wang ZQ, Fetka I, Wagner EF, Busslinger M. Complete block of early B cell differentiation and altered patterning of the posterior mid-brain in mice lacking Pax5/BSAP. Cell. 1994;79: 901-912.
13. Morrison AM, Jager U, Chott A, Schebesta M, Haas OA, Busslinger M. Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma. Blood. 1998;92:3865-3878.
14. Adams B, Dorfler P, Aguzzi A, et al. Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis. Genes Dev. 1992;6:1589-1607.
15. Krenacs L, Himmelmann AW, Quintanilla-Martinez L, et al. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood. 1998;92:1308-1316.
16. Busslinger M, Urbanek P. The role of BSAP (Pax-5) in B-cell development [review]. Curr Opin Genet Dev. 1995;5:595-601.
17. Neurath MF, Max EE, Strober W. Pax5 (BSAP) regulates the murine immunoglobulin 3′ alpha enhancer by suppressing binding of NF-alpha P, a protein that controls heavy chain transcription. Proc Natl Acad Sci U S A. 1995;92:5336-5340.
18. Max EE, Wakatsuki Y, Neurath MF, Strober W. The role of BSAP in immunoglobulin isotype switching and B-cell proliferation. Curr Topics Microbiol Immunol. 1995;194:449-458.
19. Neurath MF, Stuber ER, Strober W. BSAP: a key regulator of B-cell development and differentiation [review]. Immunol Today. 1995;16:564-569.
20. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci U S A. 1996;93:13931-13936.
21. Owen R, Parapia L, Richards S, et al. Should Waldenström's macroglobulinemia be considered part of the spectrum of marginal zone lymphoma [abstract]? Blood. 1999;94(suppl 1):385.
22. Owen R, Johnson S, Morgan G. Waldenström's macroglobulinemia: laboratory diagnosis and treatment. Hematol Oncol. 2000;18:41-49.
23. Spurbeck JL, Carlson RO, Allen JE, Dewald GW. Culturing and robotic harvesting of bone marrow, lymph nodes, peripheral blood, fibroblasts, and solid tumors with in situ techniques. Cancer Genet Cytogenet. 1988;32:59-66.
24. Jalal SM, Law ME, Stamberg J, et al. Detection of diagnostically critical, often hidden, anomalies in complex karyotypes of haematological disorders using multicolour fluorescence in situ hybridization. Br J Haematol. 2001;112:975-980.
25. Schrock E, Veldman T, Padilla-Nash H, et al. Spectral karyotyping refines cytogenetic diagnostics of constitutional chromosomal abnormalities. Hum Genet. 1997;101:255-262.
26. GabreaA, Bergsagel PL, Chesi M, Shou Y, Kuehl WM. Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Mol Cell. 1999;3:119-123.
27. Remstein ED, James CD, Kurtin PJ. Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am J Pathol. 2000; 156:1183-1188.
28. Schop R, Jalal S, Van Wier S, et al. Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genet Cytogenet. 2002;132:55-60.
29. Ahmann GJ, Jalal SM, Juneau AL, et al. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet. 1998;101: 7-11.
30. Rajkumar SV, Fonseca R, Dewald GW, et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet. 1999;113:73-77.
31. Gertz MA, Kyle RA. Hyperviscosity syndrome. J Intens Care. 1995;10:128-141.
32. Singh M, Birshtein BK. NF-HB (BSAP) is a repressor of the murine immunoglobulin heavy-chain 3′ alpha enhancer at early stages of B-cell differentiation. Mol Cell Biol. 1993;13:3611-3622.
33. Neurath MF, Strober W, Wakatsuki Y. The murine Ig 3′ alpha enhancer is a target site with repressor function for the B cell lineage-specific transcription factor BSAP (NF-HB, S alpha-BP). J Immunol. 1994;153:730-742.
34. Louviaux I, Michaux L, Hagemeijer A, et al. Cytogenetic abnormalities in Waldenström's disease (WD): a single centre study of 45 cases [abstract]. In: Proceedings of the Annual Meeting of the American Society of Hematology. 1998;92: 184b.
35. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3-21.
36. Bergsagel PL, Nardini E, Brents L, Chesi M, Kuehl WM. IgH translocations in multiple myeloma: a nearly universal event that rarely involves c-myc. Curr Top Microbiol Immunol. 1997; 224:283-287.
37. Levine EG, Arthur DC, Frizzera G, Peterson BA, Hurd DD, Bloomfield CD. There are differences in cytogenetic abnormalities among histologic sub-types of the non-Hodgkin's lymphomas. Blood. 1985;66:1414-1422.
38. Yunis JJ, Oken MM, Kaplan ME, Ensrud KM, Howe RR, Theologides A. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N Engl J Med. 1982; 307:1231-1236.
39. Chong YY, Lau LC, Lui WO, et al. A case of t(8; 14) with total and partial trisomy 3 in Waldenström macroglobulinemia. Cancer Genet Cytogenet. 1998;103:65-67.
40. San Roman C, Ferro T, Guzman M, Odriozola J. Clonal abnormalities in patients with Waldenström's macroglobulinemia with special reference to a Burkitt-type t(8;14). Cancer Genet Cytogenet. 1985;18:155-158.
41. Nishida K, Taniwaki M, Misawa S, Abe T. Nonrandom rearrangement of chromosome 14 at band q32.33 in human lymphoid malignancies with mature B-cell phenotype. Cancer Res. 1989;49: 1275-1281.
42. Calasanz MJ, Cigudosa JC, Odero MD, et al. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary break-points and clinical correlations. Genes Chromosomes Cancer. 1997;18:84-93.
43. Hirase N, Miyamura T, Ishikura H, et al. Primary macroglobulinemia with t(11;18) (q21;q21) [review]. Rinsho Ketsueki. 1996;37:340-345.
44. Hirase N, Yufu Y, Abe Y, et al. Primary macroglobulinemia with t(11;18)(q21;q21). Cancer Genet Cytogenet. 2000;117:113-117.
45. Dierlamm J, Wlodarska I, Michaux L, et al. Genetic abnormalities in marginal zone B-cell lymphoma [review]. Hematol Oncol. 2000;18:1-13.
46. Wong KF, So CC. Waldenström macroglobulinemia with karyotypic aberrations involving both homologous 6q. Cancer Genet Cytogenet. 2001; 124:137-139.
47. Mansoor A, Medeiros LJ, Weber DM, et al. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol. 2001;116:543-549.
48. Parsa NZ, Gaidano G, Mukherjee AB, et al. Cytogenetic and molecular analysis of 6q deletions in Burkitt's lymphoma cell lines. Genes Chromosomes Cancer. 1994;9:13-18.
49. Offit K, Parsa NZ, Gaidano G, et al. 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. Blood. 1993;82:2157-2162.
50. Gaidano G, Hauptschein RS, Parsa NZ, et al. Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. Blood. 1992;80: 1781-1787.
51. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343: 1910-1916.
52. Willis TG, Dyer MJS. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood. 2000;96:808-822.